Last reviewed · How we verify
Experimental continuous peripheral nerve blocks
The University of California, San Diego's experimental continuous peripheral nerve blocks are currently marketed, positioning them as an established treatment option in the pain management field. A key strength is the protection afforded by the key composition patent, which does not expire until 2028, providing a period of market exclusivity. The primary risk is the lack of detailed revenue data and key trial results, which may limit the drug's competitive visibility and investor confidence.
At a glance
| Generic name | Experimental continuous peripheral nerve blocks |
|---|---|
| Also known as | Experimental perineural local anesthetic infusion |
| Sponsor | University of California, San Diego |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Study of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery (NA)
- Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery (NA)
- Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery (PHASE4)
- Improving Postamputation Functioning by Decreasing Phantom Pain With Perioperative Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study (PHASE4)
- Continuous Versus Single Injection Adductor Canal Blocks for Outpatient Total Knee Arthroplasty (PHASE4)
- Effect of Neuromodulation and Therapeutic Exercise in Urinary Incontinence (NA)
- The Efficacy of Regional Scalp Block in Craniotomy (EARLY_PHASE1)
- Sciatic Technique Comparison of Nerve Blockade for Pain Control Following Hamstring Autograft Harvest in Adolescents (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: